Predictive factors for survival and correlation to toxicity in advanced Stage III non-small cell lung cancer patients with concurrent chemoradiation

Concurrent chemoradiotherapy is the standard treatment for locally advanced Stage III non-small cell lung cancer in patients with a good performance status and minimal weight loss. This study aimed to define subgroups with different survival outcomes and identify correlations with the radiation-rela...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Japanese journal of clinical oncology 2016-02, Vol.46 (2), p.144
Hauptverfasser:	Kim, Yong-Hyub, Ahn, Sung-Ja, Kim, Young-Chul, Kim, Kyu-Sik, Oh, In-Jae, Ban, Hee-Jung, Chung, Woong-Ki, Nam, Taek-Keun, Yoon, Mee Sun, Jeong, Jae-Uk, Song, Ju-Young
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - therapeutic use Carboplatin - administration & dosage Carcinoma, Non-Small-Cell Lung - pathology Carcinoma, Non-Small-Cell Lung - therapy Chemoradiotherapy Cisplatin - administration & dosage Deoxycytidine - administration & dosage Deoxycytidine - analogs & derivatives Drug Administration Schedule Female Humans Kaplan-Meier Estimate Lung Neoplasms - pathology Lung Neoplasms - therapy Male Middle Aged Neoplasm Staging Paclitaxel - administration & dosage Proportional Hazards Models Radiation Injuries - etiology Radiotherapy, Conformal Retrospective Studies Taxoids - administration & dosage Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Concurrent chemoradiotherapy is the standard treatment for locally advanced Stage III non-small cell lung cancer in patients with a good performance status and minimal weight loss. This study aimed to define subgroups with different survival outcomes and identify correlations with the radiation-related toxicities. We retrospectively reviewed 381 locally advanced Stage III non-small cell lung cancer patients with a good performance status or weight loss of
ISSN:	0368-2811 1465-3621
DOI:	10.1093/jjco/hyv174